Rituximab retention rate in systemic sclerosis: a long term real-life multicenter study
Key Points
Key points are not available for this paper at this time.
Abstract
to report real-life data on rituximab retention-rate as indicator of safety and efficacy in a multicentric national cohort of systemic sclerosis patients.